Cargando…

SGLT-2 inhibitors as cardioprotective agents in COVID-19

Detalles Bibliográficos
Autores principales:	Gupta, Kashish, Kunal, Shekhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508492/ https://www.ncbi.nlm.nih.gov/pubmed/33010945 http://dx.doi.org/10.1016/j.hrtlng.2020.09.002

Ejemplares similares

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects
por: Tentolouris, Anastasios, et al.
Publicado: (2019)

Evolving insights into the pleiotropic cardioprotective mechanisms of SGLT2 inhibitors
por: Fender, Anke C., et al.
Publicado: (2023)

Statins in COVID-19: A new ray of hope
por: Kunal, Shekhar, et al.
Publicado: (2020)

Cardioprotection by SGLT2 Inhibitors—Does It All Come Down to Na(+)?
por: Trum, Maximilian, et al.
Publicado: (2021)

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
por: Androutsakos, Theodoros, et al.
Publicado: (2022)

Use of Animal Models for Investigating Cardioprotective Roles of SGLT2 Inhibitors
por: Al Thani, Najlaa A., et al.
Publicado: (2023)

Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure
por: Oh, Chang-Myung, et al.
Publicado: (2019)

COVID-19 variants in India: Potential role in second wave and impact on vaccination
por: Kunal, Shekhar, et al.
Publicado: (2021)

Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis
por: Jiang, Kai, et al.
Publicado: (2021)

SGLT2 Inhibitors as Potential Anticancer Agents
por: Basak, Debasish, et al.
Publicado: (2023)

The emerging threat of multisystem inflammatory syndrome in adults (MIS-A) in COVID-19: A systematic review
por: Kunal, Shekhar, et al.
Publicado: (2022)

Thioglycosides as inhibitors of hSGLT1 and hSGLT2: Potential therapeutic agents for the control of hyperglycemia in diabetes
por: Castaneda, Francisco, et al.
Publicado: (2007)

SGLT inhibitors as antidiabetic agents: a comprehensive review
por: Kshirsagar, Rahul P., et al.
Publicado: (2020)

RAAS INHIBITORS ARE CARDIOPROTECTIVE IN PATIENTS WITH COVID-19
por: Holmes, Adam R., et al.
Publicado: (2021)

Use of SGLT‐2 inhibitor in COVID‐19: A cautionary tale
por: Yousaf, Zohaib, et al.
Publicado: (2021)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
por: Jung, Chang Hee, et al.
Publicado: (2014)

Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2
por: Oranje, Paul, et al.
Publicado: (2019)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
por: Vallianou, Natalia G., et al.
Publicado: (2021)

SGLT2 Inhibitors and Their Antiarrhythmic Properties
por: Kolesnik, Ewald, et al.
Publicado: (2022)

Neuroprotective Effect of SGLT2 Inhibitors
por: Pawlos, Agnieszka, et al.
Publicado: (2021)

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

The Multiple Effects of SGLT2 Inhibitors Suggest Potential Benefit in COVID-19 Patients
por: Soni, Shubham, et al.
Publicado: (2020)

Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1
por: Sayour, Alex Ali, et al.
Publicado: (2021)

Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
por: Vivian, Eva M
Publicado: (2014)

The Role of SGLT2 Inhibitors in Vascular Aging
por: Liu, Le, et al.
Publicado: (2021)

Electrocardiographic changes associated with SGLT2 inhibitors and non-SGLT2 inhibitors: A multi-center retrospective study
por: Wu, Victor Chien-Chia, et al.
Publicado: (2022)

Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Antidiabetic Agents
por: Sharma, Mukesh C., et al.
Publicado: (2014)

SGLT-2 inhibitors and their potential in the treatment of diabetes
por: Rosenwasser, Rebecca F, et al.
Publicado: (2013)

Recommendations on the Proper Use of SGLT2 Inhibitors
Publicado: (2019)

The Effects of SGLT2 Inhibitors on Lipid Metabolism
por: Szekeres, Zsolt, et al.
Publicado: (2021)

SGLT2 Inhibitors: the Gift that Keeps on Giving
por: Garcia, Maria Victoria Faith, et al.
Publicado: (2021)

Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021)

Euglycemic DKA Associated With SGLT2 Inhibitors
por: TakallooBakhtiari, Asieh, et al.
Publicado: (2021)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

Direct cardiac effects of SGLT2 inhibitors
por: Chen, Sha, et al.
Publicado: (2022)

Possible renoprotective mechanisms of SGLT2 inhibitors
por: Nishiyama, Akira, et al.
Publicado: (2023)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
por: Wicik, Zofia, et al.
Publicado: (2022)

Development of Matrix Metalloproteinase-2 Inhibitors for Cardioprotection
por: Bencsik, Péter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_goq006vi3sg8f2dde0lue4glil